{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:54:54Z","timestamp":1787007294887,"version":"build-2736575974"},"reference-count":140,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,8,2]]},"DOI":"10.1080\/14712598.2024.2374869","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T08:55:15Z","timestamp":1719910515000},"page":"799-814","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Long-acting delivery and therapies for neovascular age-related macular degeneration"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-154X","authenticated-orcid":false,"given":"Lucas W.","family":"Rowe","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-6777","authenticated-orcid":false,"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Retina Service, Midwest Eye Institute, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.477"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-016-0063-5"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(92)31871-8"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.10.017"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.19"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61501-9"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.016"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.01.006"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.05.017"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.03.021"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420960896"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.11.018"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318217373c"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.03.047"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31822c290f"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213453"},{"issue":"24","key":"e_1_3_4_29_1","first-page":"00029","article-title":"Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review","volume":"0039","author":"Bressler NM","year":"2024","unstructured":"Bressler NM, Kaiser PK, Do DV, et al. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review. Surv Ophthalmol. 2024;S0039-6257(24):00029\u20138.","journal-title":"Surv Ophthalmol"},{"key":"e_1_3_4_30_1","unstructured":"Commissioner O of the. FDA approves first biosimilar to treat macular degeneration disease and other eye conditions [Internet]. FDA; 2021 [cited 2024 May 15]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions"},{"key":"e_1_3_4_31_1","unstructured":"Coherus BioSciences Inc. | FDA approves coherus\u2019 CIMERLITM (ranibizumab-eqrn) as the first and only interchangeable biosimilar to lucentis\u00ae for All Five Indications with 12 months of interchangeability exclusivity. [cited 2024 May 15]. Available from: https:\/\/investors.coherus.com\/news-releases\/news-release-details\/fda-approves-coherus-cimerlitm-ranibizumab-eqrn-first-and-only\/"},{"key":"e_1_3_4_32_1","unstructured":"Research C for DE and. FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions. 2024 [cited 2024 Jun 2]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-eylea-treat-macular-degeneration-and-other-eye"},{"key":"e_1_3_4_33_1","unstructured":"Ahzantive Receives FDA Approval as New Eylea Biosimilar. Cent. Biosimilars. 2024 [cited Jul 2]. Available from: https:\/\/www.centerforbiosimilars.com\/view\/ahzantive-receives-fda-approval-as-new-eylea-biosimilar."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.09.009"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.06.023"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.060"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1667333"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081869"},{"key":"e_1_3_4_39_1","unstructured":"Wu AK Chong D Singh RP. Faricimab in the treatment landscape for retinal diseases: a review. TouchREVIEWS Ophthalmol [Internet]. 2022 [cited 2023 Oct 12]. Available from: https:\/\/www.touchophthalmology.com\/retina-vitreous\/journal-articles\/faricimab-in-the-treatment-landscape-for-retinal-diseases-a-review\/"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2699"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02553-5"},{"key":"e_1_3_4_43_1","first-page":"2218","article-title":"FARETINA-AMD- early treatment patterns and outcomes in patients with neovascular age-related macular degeneration initiating faricimab: an IRIS RegistryTM Analysis","volume":"64","author":"Borkar DS","year":"2023","unstructured":"Borkar DS, Tabano D, Garmo V, et al. FARETINA-AMD- early treatment patterns and outcomes in patients with neovascular age-related macular degeneration initiating faricimab: an IRIS RegistryTM Analysis. Invest Ophthalmol Vis Sci. 2023;64:2218.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40100"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06319-3"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S409822"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06116-y"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35759-4"},{"key":"e_1_3_4_49_1","unstructured":"Pandit SA Momenaei B Wakabayashi T et al. Real-world outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2023 [cited 2023 Dec 12]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2468653023005699"},{"key":"e_1_3_4_50_1","unstructured":"Raimondi R Falfeli T Bogdanova-Bennet A et al. Real-world outcomes of treatment resistant neovascular-age related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina [Internet]. 2023 [cited 2023 Dec 12]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2468653023006231"},{"key":"e_1_3_4_51_1","first-page":"OD79","article-title":"Early real-world outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with Faricimab","volume":"64","author":"Raslan W","year":"2023","unstructured":"Raslan W, Younis S, Fabozzi L, et al. Early real-world outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with Faricimab. Invest Ophthalmol Vis Sci. 2023;64:OD79.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02505-z"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.08.018"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15242"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-1111-x"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132758"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06329-1"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318672"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S328160"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S395577"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00445-0"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S376199"},{"key":"e_1_3_4_63_1","first-page":"451","article-title":"Real world efficacy and safety of brolucizumab in neovascular AMD: the REBEL study","volume":"62","author":"Aziz AA","year":"2021","unstructured":"Aziz AA, Khanani AM, London N, et al. Real world efficacy and safety of brolucizumab in neovascular AMD: the REBEL study. Invest Ophthalmol Vis Sci. 2021;62:451.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003769"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420975303"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.04.028"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.03.020"},{"key":"e_1_3_4_70_1","first-page":"461","article-title":"Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial","volume":"64","author":"Spitzer MS","year":"2023","unstructured":"Spitzer MS. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Invest Ophthalmol Vis Sci. 2023;64:461.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_71_1","first-page":"278","article-title":"Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration","volume":"64","author":"Korobelnik J-F","year":"2023","unstructured":"Korobelnik J-F, Schmidt-Ott UM, Schulze A, et al. Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2023;64:278.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.09.016"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00446-z"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.787644"},{"key":"e_1_3_4_76_1","unstructured":"OZURDEX. dexamethasone intravitreal implant."},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114342"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5285"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2016.04.020"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318285cb71"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0740"},{"key":"e_1_3_4_82_1","first-page":"931","article-title":"The DAVIO trial: a phase 1, open-label, dose-escalation study of a single injection of EYP-1901 (vorolanib in Durasert\u00ae platform) demonstrating reduced treatment burden in wet age-related macular degeneration","volume":"64","author":"Abbey AM","year":"2023","unstructured":"Abbey AM, Patel SS, Barakat M, et al. The DAVIO trial: a phase 1, open-label, dose-escalation study of a single injection of EYP-1901 (vorolanib in Durasert\u00ae platform) demonstrating reduced treatment burden in wet age-related macular degeneration. Invest Ophthalmol Vis Sci. 2023;64:931.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100527"},{"key":"e_1_3_4_84_1","unstructured":"EyePoint pharmaceuticals announces positive topline data from the phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD achieving all primary and secondary endpoints. EyePoint Pharmaceuticals. [Internet]. [cited 2024 Jan 13]. Available from: https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-pharmaceuticals-announces-positive-topline-data-phase-2"},{"key":"e_1_3_4_85_1","unstructured":"EyePoint pharmaceuticals announces two presentations of topline data with additional subgroup analyses from the phase 2 davio 2 clinical trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration. EyePoint Pharmaceuticals. [Internet]. [cited 2024 May 16] Available from: https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-pharmaceuticals-announces-two-presentations-topline"},{"key":"e_1_3_4_86_1","first-page":"218","article-title":"Phase 1 study of an intravitreal axitinib hydrogel-based implant for the treatment of neovascular age-related macular degeneration (nAMD)","volume":"62","author":"Wong JG","year":"2021","unstructured":"Wong JG, Chang A, Guymer RH, et al. Phase 1 study of an intravitreal axitinib hydrogel-based implant for the treatment of neovascular age-related macular degeneration (nAMD). Invest Ophthalmol Vis Sci. 2021;62:218.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_87_1","unstructured":"Ocular TherapeutixTM announces first subjects screened in phase 3 pivotal clinical trial of AXPAXLITM in Wet AMD. Ocular Therapeutix Inc. [Internet]. [cited 2024 Feb 24]. Available from: https:\/\/investors.ocutx.com\/news-releases\/news-release-details\/ocular-therapeutixtm-announces-first-subjects-screened-phase-3\/"},{"key":"e_1_3_4_88_1","unstructured":"Ocular TherapeutixTM Highlights Exceptional AXPAXLITM SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day Along with Positive 48-week Data from HELIOS NPDR Study. Ocular Therapeutix Inc. [cited 2024 Jul 2]. Available from: https:\/\/investors.ocutx.com\/news-releases\/news-release-details\/ocular-therapeutixtm-highlights-exceptional-axpaxlitm-sol-1\/"},{"key":"e_1_3_4_89_1","first-page":"211","article-title":"KSI-301: an anti-VEGF antibody biopolymer conjugate with extended half-life for treatment of neovascular retinal diseases","volume":"59","author":"Liang H","year":"2018","unstructured":"Liang H, Huang X, Ngo W, et al. KSI-301: an anti-VEGF antibody biopolymer conjugate with extended half-life for treatment of neovascular retinal diseases. Invest Ophthalmol Vis Sci. 2018;59:211.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027708"},{"key":"e_1_3_4_91_1","first-page":"4237","article-title":"Characterization of antibody biopolymer conjugate reveals superior biophysical properties compared to naked antibodies","volume":"61","author":"Su C","year":"2020","unstructured":"Su C, Correa F, Liang H, et al. Characterization of antibody biopolymer conjugate reveals superior biophysical properties compared to naked antibodies. Invest Ophthalmol Vis Sci. 2020;61:4237.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_92_1","first-page":"3122","article-title":"Efficacy, durability and safety of KSI-301 antibody biopolymer conjugate in wet AMD \u2013 Year 1 primary endpoint results from the pivotal DAZZLE study","volume":"63","author":"Regillo C","year":"2022","unstructured":"Regillo C, Ehrlich JS, Janer D, et al. Efficacy, durability and safety of KSI-301 antibody biopolymer conjugate in wet AMD \u2013 Year 1 primary endpoint results from the pivotal DAZZLE study. Invest Ophthalmol Vis Sci. 2022;63:3122.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_93_1","unstructured":"Kodiak Sciences Inc. A prospective randomized double-masked active comparator-controlled multi-center two-arm phase 3 study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal aflibercept in participants with neovascular (wet) age-related macular degeneration (wAMD) [Internet]. clinicaltrials.gov. 2024 [cited 2023 Dec 31]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04964089"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14402"},{"key":"e_1_3_4_95_1","unstructured":"Kodiak sciences announces recent business highlights and first quarter 2024 financial results. Kodiak Sciences Inc. [Internet]. [cited 2024 Jun 2]. Available from: https:\/\/ir.kodiak.com\/news-releases\/news-release-details\/kodiak-sciences-announces-recent-business-highlights-and-first\/"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1021\/bm101233m"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym13040642"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2298-9"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020288"},{"key":"e_1_3_4_100_1","first-page":"2898","article-title":"Suprachoroidal delivery of suspensions of tyrosine kinase inhibitor, complement inhibitor, and corticosteroid: preclinical and clinical correlates","volume":"61","author":"Goldstein DA","year":"2020","unstructured":"Goldstein DA, Ciulla TA. Suprachoroidal delivery of suspensions of tyrosine kinase inhibitor, complement inhibitor, and corticosteroid: preclinical and clinical correlates. Invest Ophthalmol Vis Sci. 2020;61:2898.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14042"},{"key":"e_1_3_4_102_1","first-page":"459","article-title":"Suprachoroidal injection of triamcinolone acetonide suspension: ocular pharmacokinetics and distribution in rabbits demonstrates high and durable levels in the chorioretina","volume":"38","author":"Muya L","year":"2022","unstructured":"Muya L, Kansara V, Cavet ME, et al. Suprachoroidal injection of triamcinolone acetonide suspension: ocular pharmacokinetics and distribution in rabbits demonstrates high and durable levels in the chorioretina. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2022;38:459\u2013467.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"key":"e_1_3_4_103_1","first-page":"4925","article-title":"Pharmacokinetics and ocular tolerability of suprachoroidal CLS-AX (axitinib injectable suspension) in rabbits","volume":"61","author":"Muya L","year":"2020","unstructured":"Muya L, Kansara V, Ciulla T. Pharmacokinetics and ocular tolerability of suprachoroidal CLS-AX (axitinib injectable suspension) in rabbits. Invest Ophthalmol Vis Sci. 2020;61:4925.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.7.19"},{"key":"e_1_3_4_105_1","first-page":"2194","article-title":"Long-acting potential of suprachoroidally delivered BCX4161, a selective plasma kallikrein inhibitor, for diabetic macular edema","volume":"62","author":"Muya L","year":"2021","unstructured":"Muya L, El-Kattan Y, Kansara V, et al. Long-acting potential of suprachoroidally delivered BCX4161, a selective plasma kallikrein inhibitor, for diabetic macular edema. Invest Ophthalmol Vis Sci. 2021;62:2194.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_106_1","first-page":"3977","article-title":"Suprachoroidal CLS-AX (axitinib injectable suspension), as a potential long-acting therapy for neovascular age-related macular degeneration (nAMD)","volume":"61","author":"Kaiser PK","year":"2020","unstructured":"Kaiser PK, Ciulla T, Kansara V. Suprachoroidal CLS-AX (axitinib injectable suspension), as a potential long-acting therapy for neovascular age-related macular degeneration (nAMD). Invest Ophthalmol Vis Sci. 2020;61:3977.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_107_1","first-page":"728","article-title":"Safety and tolerability study of suprachoroidal injection CLS-AX in Neovascular AMd patients with persistent activity following anti-vegf therapy (OASIS, NCT04626128; Extension Study NCT NCT05131646)","volume":"64","author":"Marcus DM","year":"2023","unstructured":"Marcus DM, Hu A, Barakat M, et al. Safety and tolerability study of suprachoroidal injection CLS-AX in Neovascular AMd patients with persistent activity following anti-vegf therapy (OASIS, NCT04626128; Extension Study NCT NCT05131646). Invest Ophthalmol Vis Sci. 2023;64:728.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316195"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479157"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1867532"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2019.0126"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.13.21"},{"key":"e_1_3_4_114_1","unstructured":"Results Posted. Safety and Tolerability of RGX-314 (investigational product) gene therapy for neovascular AMD Trial. ClinicalTrials.Gov [Internet]. [cited 2024 Jan 18]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03066258?tab=results"},{"key":"e_1_3_4_115_1","unstructured":"Study Details. Pivotal 1 Study of RGX-314 Gene Therapy in Participants with nAMD. ClinicalTrials.Gov [Internet]. [cited 2024 Jan 18] Available from: https:\/\/clinicaltrials.gov\/study\/NCT04704921"},{"key":"e_1_3_4_116_1","unstructured":"Study Details. Pivotal 2 study of RGX-314 Gene therapy in participants with nAMD. ClinicalTrials.Gov [Internet]. [cited 2024 Jan 18] Available from: https:\/\/clinicaltrials.gov\/study\/NCT05407636"},{"key":"e_1_3_4_117_1","unstructured":"REGENXBIO Announces Updated Strategic Plans and Third Quarter. Financial results. Regenxbio Inc [Internet]. 2023 [cited 2024 Jan 18] Available from: https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-announces-updated-strategic-plans-and-third-quarter\/"},{"key":"e_1_3_4_118_1","unstructured":"REGENXBIO announces positive interim data from phase II AAVIATE\u00ae Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery. Regenxbio Inc [Internet]. [cited 2024 Jan 17] Available from: https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-announces-positive-interim-data-phase-ii-aaviater\/"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1270561"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.11.003"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2021.0001"},{"key":"e_1_3_4_122_1","unstructured":"Study Details. ADVM-022 Intravitreal Gene Therapy for Wet AMD | ClinicalTrials.Gov [Internet]. [cited 2024 Jan 18] Available from: https:\/\/clinicaltrials.gov\/study\/NCT03748784"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102394"},{"key":"e_1_3_4_124_1","unstructured":"Adverum biotechnologies announces positive preliminary efficacy and safety data from LUNA Phase 2 Trial of Ixo-vec in patients with wet AMD [Internet]. [cited 2024 Feb 17] Available from: https:\/\/investors.adverum.com\/news\/news-details\/2024\/Adverum-Biotechnologies-Announces-Positive-Preliminary-Efficacy-and-Safety-Data-from-LUNA-Phase-2-Trial-of-Ixo-vec-in-Patients-with-Wet-AMD\/default.aspx"},{"key":"e_1_3_4_125_1","unstructured":"Inc 4D Molecular Therapeutics. 4DMT Receives FDA regenerative medicine advanced therapy (RMAT) Designation for 4D-150 Genetic medicine for intravitreal treatment of wet AMD the First RMAT Designation in Wet AMD [Internet]. GlobeNewswire News Room. 2023 [cited 2024 Jan 18]. Available from: https:\/\/www.globenewswire.com\/news-release\/2023\/12\/21\/2799961\/0\/en\/4DMT-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-4D-150-Genetic-Medicine-for-Intravitreal-Treatment-of-Wet-AMD-the-First-RMAT-Designation-in-Wet-AMD.html"},{"key":"e_1_3_4_126_1","unstructured":"Study Details. 4D-150 in patients with neovascular (wet) age-related macular degeneration. ClinicalTrials.Gov [Internet]. [cited 2024 Jan 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05197270"},{"key":"e_1_3_4_127_1","first-page":"5055","article-title":"Interim results for the Phase 1\/2 PRISM Trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration","volume":"64","author":"Khanani AM","year":"2023","unstructured":"Khanani AM, Hershberger VS, Kay CN, et al. Interim results for the Phase 1\/2 PRISM Trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration. Invest Ophthalmol Vis Sci. 2023;64:5055.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_128_1","unstructured":"4DMT presents positive interim data from randomized phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD. 4D Molecular Therapeutics [Internet]. [cited 2024 Feb 4]. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-presents-positive-interim-data-randomized-phase-2-prism\/"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.014"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.011"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.04.004"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077117"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.001"},{"key":"e_1_3_4_134_1","unstructured":"Opthea completes enrollment in pivotal phase 3 clinical program with sozinibercept in wet. AMD - Opthea Limited Inc [Internet]. [cited 2024 Jun 2]. Available from: https:\/\/ir.opthea.com\/news-releases\/news-release-details\/opthea-completes-enrollment-pivotal-phase-3-clinical-program\/"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.107972"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.710186"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2007.02.010"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S254774"},{"key":"e_1_3_4_140_1","article-title":"AsclepiX therapeutics completes enrollment in DISCOVER Trial for neovascular age-related macular degeneration (nAMD)","author":"Ohlmeyer M","unstructured":"Ohlmeyer, M. AsclepiX therapeutics completes enrollment in DISCOVER Trial for neovascular age-related macular degeneration (nAMD) [Internet]. AsclepiX Ther. 2024 [cited 2 Jun 2024]. Available from: https:\/\/asclepix.com\/asclepix-therapeutics-completes-enrollment-in-discover-trial-for-neovascular-age-related-macular-degeneration-namd\/","journal-title":"AsclepiX Ther"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106078"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100966"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02610-z"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2374869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T15:30:42Z","timestamp":1727191842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2374869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":140,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,2]]}},"alternative-id":["10.1080\/14712598.2024.2374869"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2374869","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}